Summary of Agenus Inc. Q1 2025 Earnings Call

1Key Financial Results and Metrics

Cash Balance: $18.5 million at the end of Q1 2025, down from $40.4 million at the end of 2024.

Cash Used in Operations: $25.6 million for Q1 2025, a reduction from $38.2 million in Q1 2024.

Revenue: $24.1 million for Q1 2025, compared to $28 million in Q1 2024.

Net Loss: $26.4 million or $1.03 per share for Q1 2025, significantly improved from a net loss of $63.5 million or $3.04 per share in the same period last year.

2Strategic Updates and Business Highlights

BOT/BAL Data: New data presented at AACR 2025 shows durable responses in historically untreatable cold tumors, including MSS colorectal cancer and others.

Leadership Changes: Dr. Richard Goldberg has joined as Chief Development Officer, focusing on regulatory pathways and advancing BOT/BAL.

Operational Efficiency: The company is on track to reduce annual operational cash burn to below $50 million in the second half of 2025.

Capital Strategy: Agenus has received four formal proposals for transactions, including potential sales of their Emeryville facility and licensing deals for BOT/BAL, aimed at strengthening the balance sheet.

3Forward Guidance and Outlook

Agenus is optimistic about the regulatory environment, especially with new FDA leadership advocating for accelerated approvals of meaningful treatments.

A Type B meeting with the FDA has been formally requested to discuss BOT/BAL, with hopes for accelerated approval based on a robust data package.

The company anticipates announcing at least one of the proposed transactions in the coming weeks, which could provide significant capital.

4Bad News, Challenges, or Points of Concern

Declining Cash Reserves: The significant drop in cash reserves raises concerns about financial sustainability without new funding.

Regulatory Uncertainty: Previous interactions with the FDA resulted in a less favorable assessment of their data, which could impact approval timelines.

Market Competition: The competitive landscape in oncology remains challenging, particularly for treatments targeting colorectal cancer, where existing therapies have shown limited efficacy.

5Notable Q&A Insights

Regulatory Interactions: The company has not yet engaged with the new FDA leadership but sees the upcoming Type B meeting as a critical opportunity to present updated data.

Focus on Colorectal Cancer: The strategic focus will primarily be on colorectal cancer for regulatory discussions, with potential expansions into other tumor types later.

European Engagement: Positive interactions with European authorities regarding conditional approval pathways were noted, with plans to pursue parallel discussions with the FDA.

Emeryville Facility Valuation: There is an expectation that the value of the Emeryville facility may increase due to current trends in pharmaceutical manufacturing, although immediate capital needs are driving the decision to pursue a sale now. Overall, Agenus is navigating a complex landscape with promising data and strategic initiatives, but faces challenges related to cash reserves and regulatory hurdles.